Ozempic
GLP-1 receptor agonist. Developed by Novo Nordisk. Clinical, regulatory, and source evidence are connected below.
Latest signals
The three most recent source-backed changes linked to this drug.
Phase 2 · NOT_YET_RECRUITING · Kirby Institute
Phase 4 · RECRUITING · Ali Aminian
Phase 2 · RECRUITING · Biomea Fusion Inc.
Clinical trials
A focused view of recently updated studies · 20 linked records.
Kirby Institute · Updated Apr 3, 2026
Ali Aminian · Updated Apr 2, 2026
Biomea Fusion Inc. · Updated Mar 31, 2026
Memorial Sloan Kettering Cancer Center · Updated Mar 27, 2026
The University of Texas Health Science Center, Houston · Updated Mar 17, 2026
QuickSilver Scientific · Updated Mar 16, 2026
Regulatory timeline
Verified regulatory records in reverse chronological order.
Human medicines European public assessment report (EPAR): Wegovy, semaglutide, Date of authorisation: 06/01/2022, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Date of authorisation: 08/02/2018, Revision: 20, Status: Authorised
ACT Brief: FDA Clearance and Reimbursement for Wearables, Data Validation Across Complex Trials, and Wegovy HD ApprovalMar 23, 2026
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
PRAC assesses that NAION could be a very rare side effect of Ozempic, Rybelsus and Wegovy
Rybelsus – Rappel : risque d'erreurs médicamenteuses dû à l’introduction d'une nouvelle formulation
Wegovy and Mounjaro for weight loss not funded
La AEMPS informa del cambio de dosificación de Rybelsus (semaglutida) y los posibles errores de medicación
OZEMPIC
OZEMPIC
Related intelligence
Records connected through the current intelligence graph.
Source evidence
Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.
